Bacil Pharma Swings to Profit on Other Income, Zero Core Sales

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAbhay Singh|Published at:
Bacil Pharma Swings to Profit on Other Income, Zero Core Sales
Overview

Bacil Pharma Limited has reported a turnaround to profit for Q3 FY26, posting ₹0.0392 Cr PAT, driven entirely by 'Other Income' which surged 1050% YoY to ₹0.0645 Cr. Revenue from core operations remained at ₹0 Cr for the quarter and the nine months ended December 31, 2025. While consolidated PAT saw an 85.96% YoY jump to ₹0.7217 Cr for 9M FY26, EPS declined YoY from ₹0.66 to ₹0.52, indicating potential dilution.

🟢 SCENARIO A: For Earnings, Buybacks, or Financial Updates

The Financial Deep Dive

📉 The Numbers:

Bacil Pharma Limited's unaudited consolidated results for the quarter and nine months ended December 31, 2025, reveal a complex financial picture heavily reliant on non-core earnings.

  • Q3 FY26 vs Q3 FY25 (YoY): Total revenue experienced a substantial 1050% increase, rising from ₹0.0030 Cr to ₹0.0645 Cr. This surge was solely due to 'Other Income', which jumped 1050% YoY to ₹0.0645 Cr. 'Revenue from operations' remained flat at ₹0 Cr. Total expenses decreased by 61.08% to ₹0.0253 Cr. Consequently, the company reported a profit (PAT) of ₹0.0392 Cr, a significant turnaround from a loss of ₹-0.0620 Cr in the prior year. Basic and Diluted EPS improved to ₹0.03 from ₹-1.00.

  • Q3 FY26 vs Q2 FY26 (QoQ): Total revenue grew 17.49% to ₹0.0645 Cr, again driven by a 17.49% increase in 'Other Income'. Expenses fell 30.68% to ₹0.0253 Cr. PAT saw a sharp increase of 184.06% to ₹0.0392 Cr. EPS rose to ₹0.03 from ₹0.01.

  • 9M FY26 vs 9M FY25 (YoY): For the nine months, total revenue increased 95.45% to ₹1.1219 Cr, driven by a 95.45% rise in 'Other Income' to ₹1.1219 Cr. 'Revenue from operations' was again ₹0 Cr. Expenses decreased 32.74% to ₹0.1707 Cr. PAT grew by 85.96% to ₹0.7217 Cr. However, a critical point is the YoY decrease in Basic and Diluted EPS from ₹0.66 to ₹0.52, despite PAT growth.

📉 The Quality:

Profitability in the reported periods is entirely attributable to 'Other Income', with no contribution from the company's core 'Revenue from operations'. While the turnaround from loss to profit is superficially positive, the absence of operational revenue raises serious concerns about the sustainability and fundamental health of the business. The YoY decline in 9M EPS, juxtaposed with strong PAT growth, suggests significant share dilution during the period, a factor investors must scrutinize.

❓ The Grill:

The primary point of concern and intense scrutiny for investors is the persistent ₹0 Revenue from operations across both the quarterly and nine-month periods. All reported profits are derived from 'Other Income', the nature, source, and recurrence of which remain undisclosed in the filing. This anomaly casts doubt on the company's core business viability and its long-term operational prospects. The significant YoY EPS decline for the nine months requires management explanation regarding share issuances or other dilutive events.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.